Lipid biosynthesis pathway

The "Lipid biosynthesis pathway" refers to a metabolic network, not a specific molecule, protein, or receptor. It encompasses the enzymatic processes by which cells synthesize various classes of lipids—including fatty acids, phospholipids, cholesterol, and triglycerides—which are essential for membrane biogenesis, energy storage, and signaling[1][3][5]. Key enzymes within the pathway include acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN), ATP citrate lyase (ACLY), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), and stearoyl-CoA desaturase 1 (SCD1), among others[1][2][3]. Aberrant activation or reprogramming of lipid biosynthesis is implicated in the pathophysiology of cancers, metabolic disorders, and cardiovascular diseases, making some individual enzymes within the pathway therapeutic targets[1][5]. However, the pathway itself is not considered a single, canonical drug target, receptor, or molecule. **Important caveats:** - "Lipid biosynthesis pathway" is not the name of a single molecular target. It refers to a collection of processes and enzymes. For drug development, specific pathway components (e.g., FASN, ACC, HMGCR) are considered targets[1][2][3]. - Drugs exist that inhibit pathway components (e.g., statins for HMGCR, ACC inhibitors). These inhibit lipid synthesis indirectly by acting on component enzymes rather than the overall pathway[2]. - Pathway inhibitors may have broad systemic effects and safety concerns, but these are related to specific enzyme targets, not the pathway as a whole. **Summary:** The "Lipid biosynthesis pathway" describes a set of interconnected metabolic processes, not a singular druggable molecule or receptor. For structured data about a therapeutic target, specificity to an individual enzyme or regulator (e.g., "Fatty acid synthase" for FASN) is required[1][2][3][5].

Other names

Lipid biosynthesisLipid synthesisFatty acid synthesisLipogenesisDe novo lipid biosynthesis